Bausch & Lomb Corp
About Bausch & Lomb Corp
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $5.1B
- Net income
- -$360.0M
- Total assets
- $14.0B
- Market cap
- $5.5B
- Operating margin
- 2.2%
- Net margin
- -6.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $5.1B
- Operating expenses
- $5.0B
- Operating income
- $113.0M
- Income tax
- $35.0M
- Net income
- -$352.0M
- EPS (basic)
- $-1.02
- EPS (diluted)
- $-1.02
Balance sheet
- Total assets
- $14.0B
- Current assets
- $3.0B
- Total liabilities
- $7.5B
- Current liabilities
- $1.9B
- Shareholders’ equity
- $6.5B
Cash flow
- Operating cash flow
- $283.0M
- Investing cash flow
- -$455.0M
- Financing cash flow
- $225.0M
- Net cash flow
- $81.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $5.5B
- EPS (diluted)
- $-1.02
- Shares outstanding
- 363.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 6, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $360.0M in FY2025.
- Revenue grew 35% from FY2022 to FY2025.
- Trading 18% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Bausch & Lomb Corp.
Write a review
News about Bausch & Lomb Corp
News & sentiment via Polygon.io
